Unknown PHASE2 INTERVENTIONAL 2-arm NCT04223999

Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery) (OptimalTTF-2)

Enhancing Tumor Treating Fields for Recurrent Glioblastoma With Targeted and Individualised Skullremodeling Surgery: A Multi-center Randomized Phase 2 Trial

Sponsor: Aalborg University Hospital

Conditions Recurrent Glioblastoma

Interventions Control Skullremodeling surgery

Updated 8 times since 2020 Last updated: Jun 5, 2023 Started: Oct 1, 2020 Primary completion: Mar 1, 2024 Completion: Mar 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04223999, this PHASE2 trial focuses on Recurrent Glioblastoma and remains ongoing. Sponsored by Aalborg University Hospital, it has been updated 8 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Mar 2026 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Mar 2026 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Oct 2021 — Jul 2023 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2020 — Dec 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aalborg University Hospital
Anders Rosendal Korshøj
NovoCure GmbH
Odense University Hospital
Rigshospitalet, Denmark

Data source: University of Aarhus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aarhus, Denmark